RxDoctor Payments Data

James Griffin, MD

Family Medicine · Naples, TXNPI 1225014707

Payments from drug & device makers

$351in general payments, 2019–2025

Across 22 payments — averaging $15.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$98
  • AstraZeneca$90
  • GSK$48
  • Abbott$27
  • Amgen$26
  • Eisai Inc.$18
  • plus $43 from 3 others

What the payments were for

  • Food & beverage$351100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC6$98
AstraZeneca6$90
GSK3$48
Abbott2$27
Amgen1$26
Eisai Inc.1$18
AbbVie1$16
Pfizer1$14
Sanofi-aventis U.S. LLC1$13

How this compares

$351 in reported general payments places this provider in the 45th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$174,253
Medicare patients
507
Services billed
4,751

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban80$59,598
FarxigaDapagliflozin Propanediol50$52,682
OzempicSemaglutide34$45,182
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog45$42,515
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog19$27,452
JardianceEmpagliflozin27$26,287
LinzessLinaclotide41$25,999
JanuviaSitagliptin Phosphate15$25,230
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$22,136
Breztri AerosphereBudesonide/Glycopyr/Formoterol22$17,242
XareltoRivaroxaban18$14,894
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog15$12,305
Tresiba Flextouch U-100Insulin Degludec12$9,650
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr18$8,446
Breo ElliptaFluticasone/Vilanterol18$7,529

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$90$73,89984 claims
PfizerEliquis$14$59,59880 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$48$38,11155 claims
AbbVieLinzess$16$25,99941 claims
Sanofi-aventis U.S. LLCLantus$13$6,20523 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Naples

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →